Cancer Archives

News and Trends 21 Jul 2015

NASDAQ-listed Biotech from Boston shops cancer-treating antibodies in Italy

A new partnering deal in the trendy field of immune-oncology. Boston-based Agenus signed a €40M deal with Italian Biotech Diatheva to get antibodies, which are targeting a glycoprotein expressed on T cell and NK cell lymphocytes to boost the immune system of patients to fight major cancer. The Boston (Lexington)-based company Agenus went on the NASDAQ […]

July 21, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 21 Jul 2015

BMS steps into the European Market with its new Lung Cancer Treatment

It’s the first major treatment for metastatic squamous non-small cell lung cancer (NSCLC) to have been approved in over a decade in Europe: Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Nivolumab was granted with market authorization by the European Commission. The drug is the first to improve overall survival in previously-treated metastatic NSCLC. Just one month […]

July 21, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 20 Jul 2015

Theravectys’ HIV Cure on the Road to Success

Theravectys just announced positive results of its HIV drug candidate in a phase I/II study. The therapeutic vaccine using lentivirus could be the first cure available for the 35 million people currently suffering from this worldwide epidemic. Paris-based Theravectys presented detailed results from its phase I/II study at the 2015 Towards an HIV Cure Symposium in Vancouver, Canada. The trial currently enrolled 38 HIV-positive patients […]

July 20, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 17 Jul 2015

TC BioPharm raises €1.7M to commence treatment in UK cancer patients

TC BioPharm raised €1.7M (£1.18) to treat UK-based patients with melanoma, lung and kidney cancer. Thanks to this funding, the Phase I/II clinical studies will start as of September in several parts of the country. TC BioPharm’s lead product, ImmuniCell, uses patients’ own cells grown in culture to target a wide variety of different cancers. […]

July 17, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 15 Jul 2015

Personalized Cancer medicines are becoming reality thanks to AstraZeneca and Qiagen’s newly approved combo

A new success for personalized medicines against cancer! AstraZeneca and Qiagen’s collaboration has achieved a major milestone after receiving the FDA’s approval of Iressa, a first-line treatment for a common form of lung cancer. The drug candidate is paired with Qiagen’s therascreen EGRF test as a companion diagnostic test. There is no doubt: the future […]

July 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 9 Jul 2015

Oasmia anticipates an Oncology market growth and seeks €23M on NASDAQ

Human and veterinary oncologist Oasmia files for a €23M IPO on the American NASDAQ. The Swedish company, anticipating an increase in the oncology field, seeks to increase its visibility and to establish itself in the US. The papers have been sent, Oasmia Pharmaceutical will go to NASDAQ under the symbol OAX. The Swedish company was […]

July 9, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 8 Jul 2015

Genmab and Novartis look for the European approval of their leukemia candidate

Genmab is seeking the European authorization for Arzerra, a treatment co-developed with Novartis. The submission is based on the candidate’s positive results in its Phase III in patients with leukemia. Arzerra, the commercial name for ofatumumab, is a human monoclonal antibody that directs the body’s immune system to fight normal and cancerous B-lymphocytes. The drug […]

July 8, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 8 Jul 2015

CureVac’s mRNA Therapy is Working Against Prostate Cancer

mRNA based immunotherapies are no pipe dream anymore. Germany’s CureVac just presented encouraging results of its Phase IIa clinical study. The firm’s lead mRNA candidate CV9103 is well tolerated and immunogenic in patients with prostate cancer. Based on the favorable data, CureVac initiated a Phase IIb study with a follower prostate cancer vaccine. Just recently, […]

July 8, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 7 Jul 2015

DIY-Morphine is around the corner with recent Discoveries in Poppies

Bioproduction of future painkillers such as morphine could become a reality. Researchers from the University of York and GlaxoSmithKline Australia made crucial genetic discoveries in the morphinan synthesis pathway, which will allow its production in microbial systems or in genetically selected plant breeds. Opioid alkaloids have been used as painkillers since the dawn of time. The opium latex is […]

July 7, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 6 Jul 2015

ElsaLys Biotech grabs MABLife’s dual-acting antibody to treat cancer

French ElsaLys Biotech just acquired MABLife’s anti-CD160 antibody. Originally developed for the treatment of vascular eye diseases, the antibody also has the potential to be applied for tumor therapy. It inhibits vascular proliferation and modulates the immune system. To proliferate and migrate through the body, tumors rely on oxygen and nutrients supplies. Cancer cells initiate […]

July 6, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 3 Jul 2015

Lilly Cooperates with Immunocore to Fight Skin Cancer

Eli Lilly expands its portfolio in immune-oncology therapies. This time, Immunocore‘s lead T cell receptor-based drug, IMCgp100 is tested in combination with Lilly’s kinase inhibitors galunisertib and merestinib. This second collaboration between these two companies aims to increase drug efficacy against melanoma cancer. Melanomas are rare forms of skin cancer, that have a high potential […]

July 3, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 2 Jul 2015

Nanobiotix got the all-clear for its new Phase I/II clinical trial

The French National Agency for Medicines and Health Products gave Nanobiotix the green light to start a Phase I/II trial in two new cancer populations for its lead product, NBTXR3. This could lead to an increase in the commercial potential of this promising French Biotech. Nanobiotix is a great French Biotech company, which you can […]

July 2, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

NASDAQ-listed Biotech from Boston shops cancer-treating antibodies in Italy

BMS steps into the European Market with its new Lung Cancer Treatment

Theravectys’ HIV Cure on the Road to Success

TC BioPharm raises €1.7M to commence treatment in UK cancer patients

Personalized Cancer medicines are becoming reality thanks to AstraZeneca and Qiagen’s newly approved combo

Oasmia anticipates an Oncology market growth and seeks €23M on NASDAQ

Genmab and Novartis look for the European approval of their leukemia candidate

CureVac’s mRNA Therapy is Working Against Prostate Cancer

DIY-Morphine is around the corner with recent Discoveries in Poppies

ElsaLys Biotech grabs MABLife’s dual-acting antibody to treat cancer

Lilly Cooperates with Immunocore to Fight Skin Cancer

Nanobiotix got the all-clear for its new Phase I/II clinical trial

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!